Rifaximin a hepaticus encephalopathia kezelésében - Multicentrikus tanulmány

Translated title of the contribution: Rifaximin in the treatment of hepatic encephalopathy - A multicentric study

F. Szalay, L. Telegdy, Dóra Szeli, Tímea Csák, Anikó Folhoffer, Andrea Horváth, Margit Abonyi, Olga Szabó, Csaba Rédei, Elemér Nemesánszky

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

INTRODUCTION - Hepatic encephalopathy is a well-known neuropsychiatric syndrome occurring in patients with either acute or chronic liver diseases. Rifaximin, a non-absorbable antibiotic is accepted for the treatment of hepatic encehalopathy. Our aim was to investigate the efficacy and the safety of rifaximin in cirrhotic patients with hepatic encephalopathy in Hungary. PATIENTS AND METHODS - 49 patients (25 male and 24 female) with hepatic encephalopathy stage I., II. and III. were involved into the study. Patients were treated with rifaximin for seven days. The daily dose was 3×400 mg in tablets. The severity of hepatic encephalopathy was characterised by hepatic encephalopathy index (HEi) calculated as a score of five parameters; mental state, asterixis, ammonia level, number connection test and critical flicker frequency. Pretreatment and postreatment HEi were compared. RESULTS - The study was completed in 46 patients. The treatment was suspended in 2 patients who died in liver failure and in one because of oesophageal variceal bleeding. The plasma ammonia level decreased from 103.7 ± 46.4 μmol/L to 67.7 ± 32.3 μmol/L (p=0,007) during the treatment. The hepatic encephalopathy index improved in 39 (85%) patients, worsened in 4 (9%) and no change was observed in 3 cases (6%). Improvement was observed in patients both with Child B and Child C stages. Loose stool in two patients and nausea in one patient were the only registered side effects. No severe adverse event related to the study medication was observed. CONCLUSIONS - Rifaximin is an effective and safe medicine for the treatment of hepatic encephalopathy.

Original languageHungarian
Pages (from-to)321-325
Number of pages5
JournalLege Artis Medicinae
Volume14
Issue number5
Publication statusPublished - May 2004

Fingerprint

rifaximin
Hepatic Encephalopathy
Therapeutics
Ammonia
Hungary
Dyskinesias
Liver Failure
Nausea
Tablets

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Szalay, F., Telegdy, L., Szeli, D., Csák, T., Folhoffer, A., Horváth, A., ... Nemesánszky, E. (2004). Rifaximin a hepaticus encephalopathia kezelésében - Multicentrikus tanulmány. Lege Artis Medicinae, 14(5), 321-325.

Rifaximin a hepaticus encephalopathia kezelésében - Multicentrikus tanulmány. / Szalay, F.; Telegdy, L.; Szeli, Dóra; Csák, Tímea; Folhoffer, Anikó; Horváth, Andrea; Abonyi, Margit; Szabó, Olga; Rédei, Csaba; Nemesánszky, Elemér.

In: Lege Artis Medicinae, Vol. 14, No. 5, 05.2004, p. 321-325.

Research output: Contribution to journalArticle

Szalay, F, Telegdy, L, Szeli, D, Csák, T, Folhoffer, A, Horváth, A, Abonyi, M, Szabó, O, Rédei, C & Nemesánszky, E 2004, 'Rifaximin a hepaticus encephalopathia kezelésében - Multicentrikus tanulmány', Lege Artis Medicinae, vol. 14, no. 5, pp. 321-325.
Szalay, F. ; Telegdy, L. ; Szeli, Dóra ; Csák, Tímea ; Folhoffer, Anikó ; Horváth, Andrea ; Abonyi, Margit ; Szabó, Olga ; Rédei, Csaba ; Nemesánszky, Elemér. / Rifaximin a hepaticus encephalopathia kezelésében - Multicentrikus tanulmány. In: Lege Artis Medicinae. 2004 ; Vol. 14, No. 5. pp. 321-325.
@article{4cdc1b741c604b079b502ea95481f90d,
title = "Rifaximin a hepaticus encephalopathia kezel{\'e}s{\'e}ben - Multicentrikus tanulm{\'a}ny",
abstract = "INTRODUCTION - Hepatic encephalopathy is a well-known neuropsychiatric syndrome occurring in patients with either acute or chronic liver diseases. Rifaximin, a non-absorbable antibiotic is accepted for the treatment of hepatic encehalopathy. Our aim was to investigate the efficacy and the safety of rifaximin in cirrhotic patients with hepatic encephalopathy in Hungary. PATIENTS AND METHODS - 49 patients (25 male and 24 female) with hepatic encephalopathy stage I., II. and III. were involved into the study. Patients were treated with rifaximin for seven days. The daily dose was 3×400 mg in tablets. The severity of hepatic encephalopathy was characterised by hepatic encephalopathy index (HEi) calculated as a score of five parameters; mental state, asterixis, ammonia level, number connection test and critical flicker frequency. Pretreatment and postreatment HEi were compared. RESULTS - The study was completed in 46 patients. The treatment was suspended in 2 patients who died in liver failure and in one because of oesophageal variceal bleeding. The plasma ammonia level decreased from 103.7 ± 46.4 μmol/L to 67.7 ± 32.3 μmol/L (p=0,007) during the treatment. The hepatic encephalopathy index improved in 39 (85{\%}) patients, worsened in 4 (9{\%}) and no change was observed in 3 cases (6{\%}). Improvement was observed in patients both with Child B and Child C stages. Loose stool in two patients and nausea in one patient were the only registered side effects. No severe adverse event related to the study medication was observed. CONCLUSIONS - Rifaximin is an effective and safe medicine for the treatment of hepatic encephalopathy.",
keywords = "Ammonia, Antibiotic, Hepatic encephalopathy, Hepatic encephalopathy index, Liver cirrhosis",
author = "F. Szalay and L. Telegdy and D{\'o}ra Szeli and T{\'i}mea Cs{\'a}k and Anik{\'o} Folhoffer and Andrea Horv{\'a}th and Margit Abonyi and Olga Szab{\'o} and Csaba R{\'e}dei and Elem{\'e}r Nemes{\'a}nszky",
year = "2004",
month = "5",
language = "Hungarian",
volume = "14",
pages = "321--325",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "5",

}

TY - JOUR

T1 - Rifaximin a hepaticus encephalopathia kezelésében - Multicentrikus tanulmány

AU - Szalay, F.

AU - Telegdy, L.

AU - Szeli, Dóra

AU - Csák, Tímea

AU - Folhoffer, Anikó

AU - Horváth, Andrea

AU - Abonyi, Margit

AU - Szabó, Olga

AU - Rédei, Csaba

AU - Nemesánszky, Elemér

PY - 2004/5

Y1 - 2004/5

N2 - INTRODUCTION - Hepatic encephalopathy is a well-known neuropsychiatric syndrome occurring in patients with either acute or chronic liver diseases. Rifaximin, a non-absorbable antibiotic is accepted for the treatment of hepatic encehalopathy. Our aim was to investigate the efficacy and the safety of rifaximin in cirrhotic patients with hepatic encephalopathy in Hungary. PATIENTS AND METHODS - 49 patients (25 male and 24 female) with hepatic encephalopathy stage I., II. and III. were involved into the study. Patients were treated with rifaximin for seven days. The daily dose was 3×400 mg in tablets. The severity of hepatic encephalopathy was characterised by hepatic encephalopathy index (HEi) calculated as a score of five parameters; mental state, asterixis, ammonia level, number connection test and critical flicker frequency. Pretreatment and postreatment HEi were compared. RESULTS - The study was completed in 46 patients. The treatment was suspended in 2 patients who died in liver failure and in one because of oesophageal variceal bleeding. The plasma ammonia level decreased from 103.7 ± 46.4 μmol/L to 67.7 ± 32.3 μmol/L (p=0,007) during the treatment. The hepatic encephalopathy index improved in 39 (85%) patients, worsened in 4 (9%) and no change was observed in 3 cases (6%). Improvement was observed in patients both with Child B and Child C stages. Loose stool in two patients and nausea in one patient were the only registered side effects. No severe adverse event related to the study medication was observed. CONCLUSIONS - Rifaximin is an effective and safe medicine for the treatment of hepatic encephalopathy.

AB - INTRODUCTION - Hepatic encephalopathy is a well-known neuropsychiatric syndrome occurring in patients with either acute or chronic liver diseases. Rifaximin, a non-absorbable antibiotic is accepted for the treatment of hepatic encehalopathy. Our aim was to investigate the efficacy and the safety of rifaximin in cirrhotic patients with hepatic encephalopathy in Hungary. PATIENTS AND METHODS - 49 patients (25 male and 24 female) with hepatic encephalopathy stage I., II. and III. were involved into the study. Patients were treated with rifaximin for seven days. The daily dose was 3×400 mg in tablets. The severity of hepatic encephalopathy was characterised by hepatic encephalopathy index (HEi) calculated as a score of five parameters; mental state, asterixis, ammonia level, number connection test and critical flicker frequency. Pretreatment and postreatment HEi were compared. RESULTS - The study was completed in 46 patients. The treatment was suspended in 2 patients who died in liver failure and in one because of oesophageal variceal bleeding. The plasma ammonia level decreased from 103.7 ± 46.4 μmol/L to 67.7 ± 32.3 μmol/L (p=0,007) during the treatment. The hepatic encephalopathy index improved in 39 (85%) patients, worsened in 4 (9%) and no change was observed in 3 cases (6%). Improvement was observed in patients both with Child B and Child C stages. Loose stool in two patients and nausea in one patient were the only registered side effects. No severe adverse event related to the study medication was observed. CONCLUSIONS - Rifaximin is an effective and safe medicine for the treatment of hepatic encephalopathy.

KW - Ammonia

KW - Antibiotic

KW - Hepatic encephalopathy

KW - Hepatic encephalopathy index

KW - Liver cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=2642547431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642547431&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 321

EP - 325

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 5

ER -